Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 233.18M | $ 145.24M | $ 212.02M | $ 227.49M | $ 198.32M |
| Gross Profit | $ 233.18M | $ 133.79M | $ 204.43M | $ 220.71M | $ 192.19M |
| Operating Income | $ -320.63M | $ -376.74M | $ -251.56M | $ -139.50M | $ -75.38M |
| EBITDA | $ -265.77M | $ -326.25M | $ -299.42M | $ -186.68M | $ -143.95M |
| Net Income | $ -321.55M | $ -111.40M | $ -278.48M | $ -180.09M | $ -169.43M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 370.70M | $ 566.85M | $ 450.25M | $ 552.88M | $ 361.59M |
| Total Assets | $ 594.13M | $ 788.91M | $ 672.59M | $ 776.63M | $ 607.44M |
| Total Debt | $ 401.58M | $ 404.78M | $ 407.49M | $ 261.99M | $ 215.34M |
| Net Debt | $ 343.05M | $ 346.61M | $ 345.80M | $ 96.23M | $ 130.57M |
| Total Liabilities | $ 535.05M | $ 588.10M | $ 629.73M | $ 474.52M | $ 396.23M |
| Stockholders' Equity | $ 59.08M | $ 200.81M | $ 42.85M | $ 302.11M | $ 211.21M |
| Cash Flow | |||||
| Free Cash Flow | $ -338.69M | $ -322.28M | $ -214.85M | $ -38.94M | $ -162.59M |
| Operating Cash Flow | $ -237.47M | $ -280.02M | $ -186.29M | $ -14.79M | $ -42.74M |
| Investing Cash Flow | $ 99.33M | $ 55.78M | $ -32.55M | $ -137.62M | $ -61.33M |
| Financing Cash Flow | $ 139.42M | $ 218.75M | $ 117.57M | $ 231.68M | $ 127.71M |